Pathology Department Faculty

Education

1977-1984 Korea University, Seoul, B.S. in Biology, Summa cum Laude
1985-1987 Eastern Michigan University, Ypsilanti, MI, M.S. in Biology
1989-1993 Stanford University, Stanford, CA, Ph.D. in Cancer Biology

Current and Previous Appointments
1996-2000	Assistant Professor, Dept. of Pediatrics. Oregon Health Sciences University.
1999-2000	Joint Appointment for Assistant Professor of Cell and Developmental Biology Dept. Oregon Health Sciences University.
1999-2003	Senior Scientist, Cancer Institute, Oregon Health Sciences University.
2000-2003	Associate Professor, Dept. of Pediatrics, Oregon Health Sciences University.
2000-2003	Joint Appointment for Associate Professor of Cell and Developmental Biology Dept. Oregon Health Sciences University.
2001-2003	Director of Cell Biology Resources Facility at Oregon Child Health Research Center.
2003-present	Professor, Dept. of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University.
2003-present	Member Scientist, Massey Cancer Center, Virginia Commonwealth University.
2003-present	Professor, Dept. of Biochemistry, MCV Campus, Virginia Commonwealth University.
2003-present	Director of Oncogenomics Program, Dept. of Pathology, MCV Campus, Virginia Commonwealth University.
Scholarship
1996-2000	Principal Investigator. Inhibition of Breast Cancer Growth by IGFBP-3 (U.S. Army Breast Cancer Career Development Award)
1997-1998	Principal Investigator. Distribution and Function of Novel IGFBP in Human Breast Cancer Cells (Oregon Medical Research Foundation Award)
1997-2001	Principal Investigator. Role of IGFBP-3 Receptor in Normal and Malignant Mammary Growth: A Potential Diagnostic Parameter and new Strategy for Endocrine Therapy (U.S. Army Breast Cancer Research Idear Award)
1999-2002	Principal Investigator. A Novel Insulin-like Growth Factor Binding Protein (IGFBP-rP2) in Breast Cancer (The American Cancer Society Research Project Grant)
2000-2002	Co-Investigator (PI: Ron G. Rosenfeld). A Novel Member of the Insulin-like Growth Factor Binding Protein Superfamily in Prostate Cancer (U.S. Army Prostate Cancer Research Idea Award)
2000-2001	Principal Investigator. Induction of Neuroendocrine (NE) Diffrentiation in Non-Small Cell Lung Carcinomas (NSCLC): Potential Therapeutic Application for Enhancing Chemotherapy Sensitivity(PHS NIH National Cancer Institute Grant)
2001-2003	Principal Investigator. Human Cnacer and IGFBP-3/IGFBP-3 receptor Axis. (Pharmacia)
2002-2003	Principal Investigator. Adenovirus-Mediated IGFBP-3 Receptor Gene Therapy for Breast Tumor in an Animal Model (Oregon University System)
2002-2005	Principal Investigator. IGFBP-3 Receptor: a New Class of Cell-death Receptor in Breast Cancer (U.S. Army Breast Cancer Research Idea Award)
2004-2007	Principal Investigator. Dysregulation of the IGFBP-3/IGFBP-3 receptor axis in prostate tumorigenesis (Dept. of Defense. US Army Idea Award)
2007-2010	Principal Investigator. IGFBP-3 in prostate cancer: New paradigm for suppression of angiogenesis and chemoresistance (U.S. Army Prostate Cancer Research Idea Development Award)
2009-2012	Principal Investigator. Molecular mechanisms of IGFBP-3 regulation on GFP78-induced anti-estrogen resistance in breast cancer (U.S. Army Breast Cancer Career Development Award)

Inventions and Patents

U.S. Patent Application (PCT) OHSU Serial # 483 (2000)
“Modulation of Neuroendocrine Differentiation by Protein 25-1”
This patent application claims the use of Protein 25-1 agonists and antagonists to develop drug screening assays, and diagnostic and therapeutic methods for treatment of cancer.
Inventors: Youngman Oh, Elizabeth M. Wilson and Ron G. Rosenfeld.

U.S. Patent Application (PCT) OHSU Serial # 490 (2001)
“Induction of Apoptosis and Cell Growth Inhibition by Protein 4-33”
This patent application claims the use of Proteins IGFBP-3 and 4-33 agonists and antagonists to develop drug screening assays, and diagnostic and therapeutic methods for treatment of cancer.
Inventors: Youngman Oh, Angela R. Ingermann and Ron G. Rosenfeld.

U.S. Patent Application OHSU Serial # 506 (2000)
“Identification of Tumor-Suppressing IGFBP-3 Variants without Interference with the IGF-IGFIR Axis”
This patent application claims the use of IGFBP-3 Variants to develop research tools, drug screening assays, and potential diagnostic and therapeutic methods for treatment of cancer and tumor suppression.
Inventors: Youngman Oh, Caroline K. Buckway and Ron G. Rosenfeld.

U.S. (US12195845) and PCT (PCT/US08/73842) Patent Application (2008),
“Methods and composition of treatment of prevention of radiation-induced fibrosis”
This patent application claims the use of CTGF/IGFBP-8 antagonists for the treatment of radiation-induced fibrosis in human cancer.
Inventor: Youngman Oh

Professional Societies

The Endocrine Society
American Association for Cancer Research
American Association for the Advancement of Science
The Western Society for Pediatric Research

Selected Publications (from 94 publications)

Oh Y; Muller HL; Lamson G; Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of binding protein (BP)-3 in Hs578T human breast cancer cells: Cell surface binding and growth inhibition. J. Biol. Chem. 1993, 268(20):14964-71.

Oh Y; Muller HL; Pham H; Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 1993, 268(35):26045-48.

Oh Y; Muller HL; Ng L; Rosenfeld RG. TGF- b -induced cell growth inhibition in human breast cancer cells is mediated through IGFBP-3 action. J. Biol. Chem.,1995, 270(23):13589-92.

Oh Y, Nagalla S, Yamanaka Y, Kim H, Wilson L, Rosenfeld RG. Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7; recombinant human mac25 protein specifically binds IGF-I and IGF-II with high affinity. J. Biol. Chem. 1996, 29:30322-30325.

Yamanaka Y; Wilson EM; Rosenfeld RG; Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J. Biol. Chem., 1997, 272:30729-30734.

Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998, 47:283-293.

Yang D-H; Kim H-S; Wilson EM; Rosenfeld RG; Oh Y. Identification of glycosylated 38-Kda IGFBP-8/CTGF (IGFBP-related protein 2) and proteolytic fragments in human biological fluids and up-regluation of IGFBP-rP2 expression by TGF- b in human breast cancer cells. J. Clin. Endocrinol. Metab., 1998, 83:2593-2596.

Yamanaka Y; Fowlkes JL; Rosenfeld RG; Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells. Endocrinology, 1999, 140:1319-1328.

Hwa V; Oh Y; Rosenfeld RG. The insulin-like growth factor binding protein (IGFBP) superfamily. Endocrine Rev., 1999, 20:761-787.

Devi GR; Yang D-H; Rosenfeld RG; Oh Y. Differential effects of IGFBP-3 and its proteolytic fragments on ligand binding, cell surface association and IGFIR signaling. Endocrinology, 2000, 141:4171-4180.

Walker GE; Wilson EM; Powell D; Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGFBP-3 promoter in breast cancer cells: Molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology, 2001, 142:3817-1827.

Kim H-S; Ingermann AR; Tsubaki J; Twigg SM; Oh Y. Insulin-like growth factor binding protein-3 induces apoptosis through the activation of caspases involved in a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res., 2004, 64:2229-2237.

Jogie-Brahim S; Min H-K; Oh Y. Proteomic approach for investigation of IGF-independent actions of IGFBPs in cancer, Expert Rev. Proteomics, 2005, 2:71-86.

Walker GE; Wilson EM; Powell D; Oh Y. Neuroendocrine differentiation can be induced by Mac25/IGFBP-rP-1 and 25.1 protein in nonsmall cell lung carcinoma cells .Oncogene, 2006, 25:1943-1954.

Jogie-Brahim J; Lee YC; Lee DY; Han J; Oh Y. Insulin-like growth factor binding protein-3 (IGFBP-3) – the unexplored asthma therapeutic–blocks the effects of asthma by negatively regulating NF-kB, Journal of Clinical Investigation, 2008, in revision.

Jogie-Brahim J; Feldman D; Oh Y. Unraveling IGFBP-3 Actions in Human Disease, Endocrine Reviews, 2008, in revision.

Book Chapters

Rosenfeld RG; Beukers MW; Oh Y; Zhang H; Ling N. Insulin-like growth factor receptor physiology: Use of IGF-II analogs as probes for receptor function. "Modern Concepts of Insulin-like Growth Factors" Spencer EM, ed, Elsevier Sci. Publishing, 1991, 439-48.

Oh Y; Muller HL; Zhang H; Ling N; Rosenfeld RG. Synthesis and characterization of IGF-II analogs: Applications in the evaluation of IGF receptor function and IGF-independent actions of IGFBPs. in: "Current Directions in Insulin-like Growth Factor Research" ReRoith D and Raizada MK, eds, "Advances in Experimental Medicine and Biology" Plenum Press, NY 1994, vol. 343:41-54.

Oh Y ; Yamanaka Y; Kim H-S; Vorwerk P; Wilson E; Hwa V;Yang D-H; Apagnoli A; Wanek ; Rosenfeld RG. IGF-independent actions of IGFBPs. in: "Molecular Mechanisms to Regulate the Activities of Insulin-like Growth Factors" Takano K, Hizuka N and Takahashi S-I, eds, " Excerpta Medica International Congress Series 1151" Elservier Science B. V., Amsterdam, 1998, 125-134.

Oh Y; Rosenfeld RG. IGF-independent actions of IGF binding proteins. in "The IGF System: Molecular Biology, Physiology, and Clinical Applications” Rosenfeld RG and Roberts Jr CT, eds, " Contemporary Endocrinology" Humana Press, NJ 1999, vol. 17:257-272.

Hwa V; Oh Y; Burren CP; Choi WK; Graham DL; Ingerman A; Kim H-S; Lopez-Bermejo A; Minniti G; Nagalla SR; Pai K; Spagnoli A; Vorwerk P; Wanek D; Wilson EM; Yamanaka Y; Yang D-H; Rosenfeld RG. The IGF binding protein superfamily. in "The IGF System: Molecular Biology, Physiology, and Clinical Applications” Rosenfeld RG and Roberts Jr CT, eds, " Contemporary Endocrinology" Humana Press, NJ 1999, vol. 17:315-328.

Minniti G; Oh Y. Insulin-like growth facotor binding proteins in endocrine-related neoplasia. In “Endocrine Oncology’ Ethier SP, ed, “Contemporary Endocrinology" Humana Press, NJ 2000, vol. 17:215-236.

Werner H; Oh Y; Roberts CT Jr. Apoptosis in breast cancer. In “Programmed Cell Death Volume II: Role in Disease, athogenesis and Prevention” Mattson MP, Estus S, Rangnekar V, eds, “Advances in Cell Aging and Gerontology “ Elsevier Science, Netherlands, 2001, vol. 6:1-22.

Walker GE; Kim H-S; Yang Y-F; Oh Y. IGF-independent effects of the IGFBP Superfamily. In “Insulin-like Growth Factor” Le Roith D, Zumkeller W, Baxter R, eds, Landes Bioscience, 2003.

Invited or Keynote Addresses

Invited speaker, Proceedings of the Second International Workshop on IGF Binding Proteins, OPIO (Côte D'Azur), France, Aug. 1992.

Invited speaker, Third International Symposium on Insulin-like Growth Factors, Sydney, Australia, Feb. 1994.

Invited speaker, The 77th Annual Meeting of The Endocrine Society, Washington, DC, June 1995.

Invited speaker, Third International Symposium on Insulin-like Growth Factor Binding Proteins, Tuebingen, Germany, Oct. 1995.

Invited speaker, The 10th International Congress of Endocrinology, San Francisco, CA, June 1996.

Invited speaker, Assessment of The Growth Hormone/ IGF-I Axis in Aging, Bethesda, MD, April 1997.

Invited speaker, The 5th Joint Meeting of the European Society for Pediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society, Stockholm, Sweden, June 1997.

Invited speaker, The Annual Meeting of Korean Pediatirc Endocrinology, Seoul, Korea, Oct. 1997.

Invited speaker, The 4th International Symposium on Insulin-like Growth Factors, Tokyo, Japan, Oct. 1997.

Invited speaker, The 11th Asia-Oceania Congress of Endocrinology, Seoul, Korea, April 1998.

Invited speaker, 9th International Novo Nordisk hGH Symposium, Lyon, France, April 1998.

Invited speaker, The 80th Annual Meeting of The Endocrine Society, New Orleans, Louisiana, June 1998.

Invited speaker, The 1998 International Hannah Symposium: Endocrine Signalling and the Mammary Gland, Kevoka, UK, Sept. 1998.

Invited speaker, The 15th Annual Meeting of the German Pediatric Endocrinology, Magdeburg, Germany, Nov. 1998.

Invited speaker, The 5th International Symposium on Insulin-like Growth Factors, Brighton, United Kingdom, Oct. 1999.

Invited speaker, The 84th Annual Meeting of The Endocrine Society, San Francisco, California, June 2002.

Invited speaker, International Symposium on the Functional Role of Insulin-like Growth Factor-Binding Proteins, Tuebingen, Germany, Nov. 2002.

Invited speaker, Pharmacia Distingushed Scientist Speaker Program, Tokyo, Japan, Nov, 2003.

Invited speaker, 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, Crete, Greece, Oct. 2004.

Invited speaker, International Biomedical Science Conference, Yunnan, China, Dec. 2004.

Invited speaker, The 87th Annual Meeting of The Endocrine Society, San Diego, California, June 2005.

Invited speaker, The “Era of Hope”, Department of Defense Breast Cancer Research Program Meeting, Philadelphia, Pennsylvania, June 2005.

Invited speaker, “Pathophysiology of IGF system in prostate Cancer”, The Richmond Chapter of the US TOO Prostate Cancer Support Group Meeting, Richmond, Virginia, March 2006.

Invited speaker, “Role of IGF system in human cancer, aging and inflammatory diseases”, Grand Rounds, State Key Laboratory of Molecular Oncology, Beijing, China, Nov. 2006.

Invited speaker, “Novel NF-kB Inhibitory Action of IGFBP-3 in Human Cancer: New Paradigm for Suppression of Angiogenesis, Metastasis and Chemo/Radio-resistance in Human Cancer Cells”, The 3rd International Congress of the GRS and the IGF Society Meeting, Kobe, Japan Nov. 2006.

Invited speaker, “A Novel Target for Asthma, COPD and Arthritis”, The 4th International Congress of the GRS and the IGF Society Meeting, Genoa, Italy, Sept. 2008.

back to faculty page

Updated July 21, 2009